amylin glp-1 dual agonist Identification and utility exploration of a highly potent and long-acting bullfrog analogue in GLP-1 and combination therapy GIPR/GLP-1R dual agonist therapies for

Currently available treatment with proven outcomes Semaglutide FDA-approved for diabetes (Ozempic), obesity (Wegovy), and CV risk reduction with 7+ years of clinical and post-marketing data Cardiovascular risk reduction Semaglutide SELECT trial demonstrated 20% MACE reduction in 17,604 patients -- the first anti-obesity drug with proven cardiovascular benefit Maximum weight loss potential Retatrutide Phase 2 data showed 24.2% weight loss at 48 weeks with weight curves still declining, though Phase 3 confirmation is required Metabolic liver disease (MASLD/MASH) Retatrutide Glucagon receptor agonism directly promotes hepatic fat oxidation, a mechanistic advantage for liver-specific outcomes Oral administration preference Semaglutide Only incretin-class drug available as an oral tablet (Rybelsus), with higher-dose oral formulations under development Type 2 diabetes with established treatment guidelines Semaglutide Integrated into clinical guidelines with multiple approved doses and formulations, extensive comparative data, and guideline positioning Continue Your Research Get comparison updates We publish new head-to-head comparisons regularly

Comparative effectiveness of bariatric surgeries in patients with obesity and type 2 diabetes mellitus: a network meta-analysis of randomized controlled trials

BMI, Body mass index

This twice daily injectable established the entire drug class

Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: insights from the SUSTAIN 1-7 trials